

——ATLANTA——— LUNG CANCER SYMPOSIUM™

*Times provided in ET Agenda subject to change

Agenda subject to cha	Agenda subject to change				
*Time	Topic				
7:55–8:00 AM	Welcome and Introductions Suresh Ramalingam, MD, FACP, FASCO Ticiana A. Leal, MD				
Plenary 1: Locally Advanced/Advanced NSCLC/SCLC Co-Chair: Ioana Bonta, MD					
8:00-8:15 AM	Small Cell Lung Cancer: New Therapeutic Advances in 2024 Taofeek K. Owonikoko, MD, PhD				
8:15-8:30 AM	First Line Therapy for Advanced NSCLC Without Driver Mutations Julie Brahmer, MD				
8:30-8:45 AM	Salvage Therapy for Advanced NSCLC: Reasons for Hope? Karen L. Reckamp, MD				
8:45-9:00 AM	Locally Advanced NSCLC: Radiotherapy Considerations Sibo Tian, MD				
9:00-9:15 AM	Locally Advanced NSCLC: Role of IO and Emerging Advances Ticiana A. Leal, MD				
9:15-9:30 AM	Panel Discussion				
9:30-10:15 AM	Morning Symposium and Exhibits				
Plenary 2: Early-Stage NSCLC Co-Chairs: Mohan Krishnamachary, MD and Ticiana A. Leal, MD					
10:15-10:30 AM	Neoadjuvant Therapy for Resectable NSCLC Paul Bunn, MD				
10:30-10:45 AM	Early-Stage NSCLC: When is Sub-Lobar Resection Appropriate? Onkar Khullar, MD, MSc				
10:45-11:00 AM	Adjuvant Therapy for Oncogene-Addicted NSCLC Jamie E. Chaft, MD				
11:00-11:40 AM	DEBATE: Should Adjuvant IO Be Given After Surgery Following Chemo-IO Yes: John V. Heymach, MD, PhD No: Ryan Gentzler, MD				
11:40- 11:55 AM	Panel Discussion				



——ATLANTA——LUNG CANCER SYMPOSIUM™

Plenary	3: Targe	ted Thera	apy in Ac	lvanced	INSCLC
---------	----------	-----------	-----------	---------	---------------

Co-Chairs: William S. Jonas, MD and Jennifer W. Carlisle, MD

12:40-12:55 рм	EGFR Inhibition in Locally Advanced and Stage IV NSCLC
	Suresh Ramalingam, MD, FACP, FASCO
12:55-1:10 рм	Treatment of ALK-Positive Advanced NSCLC
	Shirish M. Gadgeel, MD
1:10-1:25 РМ	KRAS Inhibition in Advanced NSCLC
	John V. Heymach, MD, PhD
1:25-1:40 PM	Panel Discussion
1:40-2:00 PM	Afternoon Break and Exhibits

Plenary 4: Targeted Therapy in Advanced NSCLC II and Rare Thoracic Malignancies

Co-Chairs: Paul Gill, MD and Steve McCune, MD

2:00-2:15 рм	Liquid Biopsy: Current and Future Applications
	Valsamo Anagnostou, MD
2:15-2:30 РМ	EGFR Exon 20 Insertion and Uncommon EGFR Mutations
	Jennifer W. Carlisle, MD
2:30-2:45 РМ	RET, MET and ROS1: Optimal Therapy and Emerging Agents
	Conor E. Steuer, MD
2:45-3:00 РМ	Systemic Therapy for HER-2, BRAF and NTRK
	Gregory J. Riely, MD, PhD
3:00-3:15 РМ	Rare Thoracic Malignancies: Mesothelioma and Thymic Malignancies
	Fatemeh Ardeshir, MD, MSc
3:15-3:30 PM	Panel Discussion
3.23 3.30 TW	T WHICH DISCUSSION
3:30-3:45 PM	Closing Remarks and Adjourn